The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily
Abstract
Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble more the pathophysiology and phenotype of complement-mediated thrombotic microangiopathies (TMA), rather than sepsis-induced coagulopathy or disseminated intravascular coagulation (DIC).1, 2 Since effective treatment is available for complement-mediated TMA,3 we aim to systematically describe relevant features (clinical phenotype, pathophysiology and management) in patients with severe COVID-19 infection. TMA is characterized by microangiopathic haemolytic anaemia, thrombocytopenia and organ damage, such as neurological, renal and cardiac dysfunction. Patients described by Zhang et al. presented with anaemia, increased lactate dehydrogenase (LDH), thrombocytopenia and organ damage (neurological in all patients and cardiac in one).2 Catastrophic antiphospholid syndrome (CAPS) is a plausible diagnosis that could not be confirmed, because of the requirement to repeat testing in 12 weeks. Even in this case, the clinical presentation, pathophysiology, and management that will be described below, would also match those of complement-mediated TMA.4 Indeed, increased LDH and thrombocytopenia have been reported in COVID-19 infection. Unfortunately, there are no reports of schistocytes to confirm microangiopathic haemolytic anaemia, probably due to the urgency of the pandemic and everyday difficulties in organizing sample transfer. Similarly, little is known on the nature of cardiac dysfunction in COVID-19. Myocarditis or inflammatory-induced cardiac damage have been postulated, but pathophysiological evidence points towards microvascular thrombosis, similar to that of TMA.1 Lastly, renal dysfunction, another characteristic of complement-mediated TMA, is also common in patients with severe COVID-19 infection.5 Complement activation plays a central role in the pathophysiology of TMAs. Complement-mediated TMAs are described by a two-hit disease model that applies for atypical haemolytic uraemic syndrome (aHUS), CAPS, transplant-associated thrombotic microangiopathy (TA-TMA) and HELLP (haemolysis, elevated liver enzyme and low platelet count) syndrome.6 The first hit results from germline mutations or acquired alterations in complement regulatory proteins or C3 convertase components. Commonly associated triggers of the second hit are pregnancy, inflammation, surgery or autoimmunity.3 The complement system is part of the immune system providing innate defence against microbes and mediating inflammatory responses. Except for inflammation, a link also exists between the complement system and platelet activation, leukocyte recruitment, endothelial cell activation and coagulation (Fig 1). Briefly, proximal complement is activated through the alternative, classical, and lectin pathways. The three pathways lead to C3 activation and C3 convertase formation. C3 activation through the alternative pathway of complement amplifies this response, culminating in pronounced C3 fragment deposition on target cells. In the presence of increased surface density of deposited C3b, the terminal (lytic) pathway is triggered, leading to C5b-9 or membrane attack complex (MAC) formation on the surface of target cells.3 A common denominator of complement-mediated effects in TMAs is endothelial dysfunction and microvascular thrombosis. Recent evidence suggests that the same is true also for COVID-19 infection. Indeed, pericytes with high expression of angiotensin-converting enzyme 2 (ACE2) are target cells of COVID-19 resulting in endothelial cell and microvascular dysfunction. Since heart-failure patients have increased ACE2 expression, they are expected to be of high risk of cardiac injury due to COVID-19.7 Similarly, ACE2 is highly expressed on podocytes and tubule epithelial cells of the kidney, whereas a recent study has suggested viral tropism for the kidney.8 Furthermore, studies of previous coronaviruses have shown that blocking C3 activation significantly attenuates the lung-directed proinflammatory sequelae of infections. Both the genetic absence of C3 and blockade of downstream complement effectors have shown therapeutic promise by containing the detrimental proinflammatory consequences of viral spread mainly via inhibition of monocyte/neutrophil activation and immune cell infiltration into the lungs.9, 10 A recent study also revealed that coronaviruses' (SARS-CoV, MERS-CoV and SARS-CoV-2) proteins bind to a key protein of the lectin pathway [MASP-2 (Mannan-binding lectin serine protease 2)], leading to complement-mediated inflammatory lung injury.11 In addition, Magro et al. have recently shown deposits of C5b-9, C4d, and MAPS-2 in the microvasculature of lung and skin biopsies of severe COVID-19 patients.12 These data are consistent with excessive activation of both the alternative and the lectin pathway of complement. Taken together, these data suggest that the 'two-hit' hypothesis needs to be further investigated in patients with severe COVID-19 in
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 1×
“Similarly, ACE2 is highly expressed on podocytes and tubule epithelial cells of the kidney, whereas a recent study has suggested viral tropism for the kidney.(8) Furthermore, studies of previous coronaviruses have shown that blocking C3 activation significantly attenuates the lungdirected proinflammatory sequelae of i…”
BackgroundCoagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179
Chen, L., Li, X., Chen, M., Feng, Y., & Xiong, C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa078 · Cited by 1,163 · cited 5×
“Similarly, little is known on the nature of cardiac dysfunction in COVID-19.”
BackgroundInfluential
Cited by
The unique characteristics of COVID-19 coagulopathy
Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020) · Critical Care · doi:10.1186/s13054-020-03077-0 · Cited by 533
Holter, J. C., Pischke, S. E., de Boer, E., Lind, A., Jenum, S., Holten, A. R., Tonby, K., Barratt-Due, A., Sokolova, M., Schjalm, C., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010540117 · Cited by 395
The complement system in COVID-19: friend and foe?
Java, A., Apicelli, A. J., Liszewski, M. K., Coler-Reilly, A., Atkinson, J. P., Kim, A. H. J., & Kulkarni, H. S. (2020) · JCI Insight · doi:10.1172/jci.insight.140711 · Cited by 376
Yu, J., Yuan, X., Chen, H., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2020) · Blood · doi:10.1182/blood.2020008248 · Cited by 374
Self-citationThe Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis
Wessels, I., Rolles, B., & Rink, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01712 · Cited by 336
Metadata
- Authors
- Gavriilaki, E., & Brodsky, R. A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2020-05-23
- Volume
- 189
- Issue
- 6
- Pages
- e227-e230
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W3021590393
- Cited by
- 178
- References
- 3
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.